

HAWKE'S BAY CLINICAL RESEARCH COMMITTEE REPORT

CLINICAL TRIALS WITHIN THE MEDICAL SERVICE

AFFINITY - An Australian-lead, Investigator-initiated, Multi-centre, Prospective, Randomised, Parallel group, Double-blind, Placebo-controlled trial to establish the effect(s) of routine administration of fluoxetine (20 mg once daily) in patients with recent stroke.

Principal Investigator: Dr John Gommans

CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

Principal Investigator: Dr Robert Leikis

IDEA - A Randomised, Double-blinded, Placebo-controlled Study of Kivia™ 575mg Zyactinase® Capsule for the Improvement of Digestive Health Parameters in Subjects with Irritable Bowel Syndrome with Constipation Symptoms.

Principal Investigator: Dr Malcolm Arnold

MK0822 – A blinded extension to 5 years for: A Phase 111 Randomised, Placebo-controlled Clinical Trial to assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Menopausal women treated with Vitamin D and Calcium.

Enrolment has closed.

Principal Investigator: Dr Robert Leikis

MODIFY 1 A Phase 111 Randomised, Double blind Placebo controlled Adaptive Design Study of the Efficacy, Safety and Tolerability of a single infusion of monoclonal antibodies in patients receiving antibiotic therapy for Clostridium Difficile Infection.

Principal Investigator: Dr Andrew Burns

REDUCE-IT – A multicentre, prospective, randomised, double blind, placebo controlled, parallel group study to evaluate the effect of AMR101 (a fish oil compound) on cardiovascular health and mortality in hypertriglyceridemic patients with cardiovascular disease (or at high risk of CV disease).

Principal Investigator: Dr Richard Luke

REWIND – A phase 111 trial of GLP-1 intervention for Diabetes Evaluation.

This study is designed to assess the effect of Dulaglutide on major cardiovascular events in patients with Type 2 Diabetes.

Enrolment has closed.

Principal Investigator: Dr Miles Williams